No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals

Trials

Volumn 17, Issue 1, 2016, Pages

  Gabler, Nicole B ^a   Duan, Naihua ^b   Raneses, Eli ^a   Suttner, Leah ^a   Ciarametaro, Michael ^c   Cooney, Elizabeth ^a   Dubois, Robert W ^c   Halpern, Scott D ^a,d   Kravitz, Richard L ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c National Pharmaceutical Council   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heterogeneity of treatment effects; Methodology; Multivariable risk index; Randomized controlled trial; Subgroup analysis

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FUNDING; HUMAN; LOGISTIC REGRESSION ANALYSIS; PATIENT DECISION MAKING; PHYSICIAN; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL MODEL; BIBLIOMETRICS; JOURNAL IMPACT FACTOR; METHODOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROCEDURES; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; STATISTICS AND NUMERICAL DATA;

BIBLIOMETRICS; DATA INTERPRETATION, STATISTICAL; HUMANS; JOURNAL IMPACT FACTOR; LOGISTIC MODELS; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84978251081     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-016-1447-5     Document Type: Article

References (30)

1. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661-87.
2. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
3. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298(10):1209-12.
4. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34(2):464-7.
5. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation. 2002;105(8):917-22.
6. Kraemer HC, Frank E, Kupfer DJ. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA. 2006;296(10):1286-9.
7. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917-30.
8. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-86.
9. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-94.
10. Varadhan R, Stuart EA, Louis TA, Segal JB, Weiss CO. Review of Guidance Documents for Selected Methods in Patient Centered Outcomes Research. Standards in Addressing Heterogeneity of Treatment Effects in Observational and Experimental Patient Centered Outcomes Research. 2012. Retrieved from http://www.pcori.org/assets/Standards-in-Addressing-Heterogeneity-of-Treatment-Effectiveness-in-Observational-and-Experimental-Patient-Centered-Outcomes-Research.pdf.
11. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-94.
12. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355(9209):1064-9.
13. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review. BMJ. 2011;342:d1569.
14. Sun X, Briel M, Busse JW, You JJ, Akl EA, Mejza F, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ. 2012;344:e1553.
15. Kasenda B, Schandelmaier S, Sun X, von Elm E, You J, Blumle A, et al. Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. BMJ. 2014;349:g4539.
16. Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials. 2009;10:43.
17. Parker AB, Naylor CD. Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J. 2000;139(6):952-61.
18. Hernandez AV, Boersma E, Murray GD, Habbema JD, Steyerberg EW. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J. 2006;151(2):257-64.
19. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schunemann HJ, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res. 2006;447:247-51.
20. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113(2):104-11.
21. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31(1):150-3.
22. Chew M, Villanueva EV, Van Der Weyden MB. Life and times of the impact factor: retrospective analysis of trends for seven medical journals (1994-2005) and their editors' views. J R Soc Med. 2007;100(3):142-50.
23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.
24. Moreira Jr ED, Stein Z, Susser E. Reporting on methods of subgroup analysis in clinical trials: a survey of four scientific journals. Braz J Med Biol Res. 2001;34(11):1441-46.
25. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363(9413):915-24.
26. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353(9170):2105-10.
27. Hayward RA, Kent DM, Vijan S, Hofer TP. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol. 2006;6:18.
28. Wessler BS, Lai Yh L, Kramer W, Cangelosi M, Raman G, Lutz JS, et al. Clinical prediction models for cardiovascular disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database. Circ Cardiovasc Qual Outcomes. 2015;8(4):368-75.
29. Iwashyna TJ, Burke JF, Sussman JB, Prescott HC, Hayward RA, Angus DC. Implications of heterogeneity of treatment effect for reporting & analysis of randomized trials in critical care. Am J Respir Crit Care Med. 2015;192(9):1045-51.
30. Burke JF, Hayward RA, Nelson JP, Kent DM. Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes. 2014;7(1):163-9.